A detailed history of Shell Asset Management CO transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Shell Asset Management CO holds 6,197 shares of ALNY stock, worth $1.52 Million. This represents 0.08% of its overall portfolio holdings.

Number of Shares
6,197
Previous 2,973 108.44%
Holding current value
$1.52 Million
Previous $722,000 136.01%
% of portfolio
0.08%
Previous 0.03%

Shares

26 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

BUY
$233.81 - $287.01 $753,803 - $925,320
3,224 Added 108.44%
6,197 $1.7 Million
Q1 2024

Jul 31, 2024

BUY
$146.51 - $198.2 $116,182 - $157,172
793 Added 36.38%
2,973 $722,000
Q1 2024

May 14, 2024

SELL
$146.51 - $198.2 $237,492 - $321,282
-1,621 Reduced 42.65%
2,180 $326,000
Q4 2023

Feb 14, 2024

SELL
$151.41 - $196.57 $156,103 - $202,663
-1,031 Reduced 21.34%
3,801 $728,000
Q3 2023

Nov 08, 2023

SELL
$170.77 - $211.65 $13,149 - $16,297
-77 Reduced 1.57%
4,832 $856,000
Q2 2023

Jul 28, 2023

SELL
$185.01 - $212.05 $18,315 - $20,992
-99 Reduced 1.98%
4,909 $932,000
Q1 2023

May 15, 2023

BUY
$182.66 - $235.53 $89,868 - $115,880
492 Added 10.89%
5,008 $1 Million
Q4 2022

Feb 07, 2023

SELL
$185.53 - $241.31 $64,378 - $83,734
-347 Reduced 7.14%
4,516 $1.07 Million
Q3 2022

Nov 14, 2022

SELL
$138.54 - $232.0 $262,948 - $440,336
-1,898 Reduced 28.07%
4,863 $973,000
Q2 2022

Aug 09, 2022

BUY
$120.42 - $169.29 $76,948 - $108,176
639 Added 10.44%
6,761 $986,000
Q1 2022

May 04, 2022

BUY
$127.18 - $173.91 $39,934 - $54,607
314 Added 5.41%
6,122 $1 Million
Q4 2021

Feb 09, 2022

BUY
$159.56 - $209.29 $327,576 - $429,672
2,053 Added 54.67%
5,808 $985,000
Q3 2021

Nov 04, 2021

SELL
$169.75 - $207.73 $29,197 - $35,729
-172 Reduced 4.38%
3,755 $709,000
Q2 2021

Aug 12, 2021

BUY
$128.63 - $176.89 $123,484 - $169,814
960 Added 32.36%
3,927 $666,000
Q1 2021

May 10, 2021

BUY
$126.83 - $175.69 $19,404 - $26,880
153 Added 5.44%
2,967 $419,000
Q4 2020

Feb 16, 2021

SELL
$122.97 - $147.0 $7,255 - $8,673
-59 Reduced 2.05%
2,814 $366,000
Q3 2020

Nov 13, 2020

SELL
$121.19 - $165.49 $38,296 - $52,294
-316 Reduced 9.91%
2,873 $418,000
Q2 2020

Aug 10, 2020

SELL
$104.21 - $156.44 $137,036 - $205,718
-1,315 Reduced 29.2%
3,189 $472,000
Q1 2020

May 11, 2020

BUY
$93.12 - $133.99 $9,312 - $13,399
100 Added 2.27%
4,504 $490,000
Q4 2019

Feb 13, 2020

SELL
$74.51 - $124.23 $95,968 - $160,008
-1,288 Reduced 22.63%
4,404 $507,000
Q2 2019

Aug 12, 2019

BUY
$65.86 - $92.79 $113,937 - $160,526
1,730 Added 43.66%
5,692 $413,000
Q4 2018

Feb 13, 2019

SELL
$62.67 - $88.33 $122,457 - $172,596
-1,954 Reduced 33.03%
3,962 $289,000
Q3 2018

Nov 13, 2018

SELL
$87.52 - $122.67 $345,353 - $484,055
-3,946 Reduced 40.01%
5,916 $518,000
Q2 2018

Aug 10, 2018

SELL
$88.31 - $107.8 $181,918 - $222,068
-2,060 Reduced 17.28%
9,862 $971,000
Q1 2018

May 14, 2018

SELL
$115.92 - $148.54 $1.37 Million - $1.76 Million
-11,849 Reduced 49.85%
11,922 $1.42 Million
Q4 2017

Feb 09, 2018

BUY
$114.49 - $139.98 $2.72 Million - $3.33 Million
23,771
23,771 $3.02 Million

Others Institutions Holding ALNY

About ALNYLAM PHARMACEUTICALS, INC.


  • Ticker ALNY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 123,028,000
  • Market Cap $30.2B
  • Description
  • Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...
More about ALNY
Track This Portfolio

Track Shell Asset Management CO Portfolio

Follow Shell Asset Management CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Shell Asset Management CO, based on Form 13F filings with the SEC.

News

Stay updated on Shell Asset Management CO with notifications on news.